DAVID SHERBONDY: Open Payments
NPI 1477572840 · GREENVILLE, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,073 in 173 payments from 20 companies in 2025. Trend: 2023 $3,442 · 2024 $3,696 · 2025 $3,073
Food & beverage: $3,073
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $351 |
| ABBVIE INC. | 30 | $306 |
| Lundbeck LLC | 11 | $283 |
| Vanda Pharmaceuticals Inc. | 16 | $265 |
| Axsome Therapeutics, Inc. | 18 | $246 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $204 |
| Otsuka America Pharmaceutical, Inc. | 16 | $204 |
| Bausch Health US, LLC | 9 | $192 |
| Almatica Pharma LLC | 10 | $161 |
| Noven Therapeutics, LLC | 8 | $148 |
Products named: REXULTI, CAPLYTA, VRAYLAR, HETLIOZ, Auvelity, TRINTELLIX, APLENZIN, LOREEV XR.
Industry payments across SC — which companies pay providers there.
